MX2022011260A - Consorcios microbianos para el tratamiento de enfermedad. - Google Patents

Consorcios microbianos para el tratamiento de enfermedad.

Info

Publication number
MX2022011260A
MX2022011260A MX2022011260A MX2022011260A MX2022011260A MX 2022011260 A MX2022011260 A MX 2022011260A MX 2022011260 A MX2022011260 A MX 2022011260A MX 2022011260 A MX2022011260 A MX 2022011260A MX 2022011260 A MX2022011260 A MX 2022011260A
Authority
MX
Mexico
Prior art keywords
disease
treatment
microbial consortia
degradation
subject
Prior art date
Application number
MX2022011260A
Other languages
English (en)
Inventor
Lee Swem
Dante Ricci
Ariel R Brumbaugh
John Cremin
Joshua J Hamilton
Shital Tripathi
Lauren Wong
Heather Romasko
Racquel Bracken
Emily Drabant Conley
Anthony Rush
Original Assignee
Federation Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Federation Bio Inc filed Critical Federation Bio Inc
Publication of MX2022011260A publication Critical patent/MX2022011260A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

La presente invención proporciona consorcios microbianos capaces de injertarse de manera estable en el tracto gastrointestinal de un sujeto, y la degradación de un sustrato metabólico asociado con enfermedad, y métodos para usar los mismos.
MX2022011260A 2020-03-10 2021-03-10 Consorcios microbianos para el tratamiento de enfermedad. MX2022011260A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062987757P 2020-03-10 2020-03-10
PCT/US2021/021790 WO2021183701A1 (en) 2020-03-10 2021-03-10 Microbial consortia for the treatment of disease

Publications (1)

Publication Number Publication Date
MX2022011260A true MX2022011260A (es) 2022-12-15

Family

ID=77670822

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011260A MX2022011260A (es) 2020-03-10 2021-03-10 Consorcios microbianos para el tratamiento de enfermedad.

Country Status (9)

Country Link
US (1) US20230125976A1 (es)
EP (1) EP4117694A1 (es)
JP (1) JP2023517235A (es)
KR (1) KR20220166803A (es)
AU (1) AU2021234298A1 (es)
CA (1) CA3175041A1 (es)
IL (1) IL296218A (es)
MX (1) MX2022011260A (es)
WO (1) WO2021183701A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113969251B (zh) * 2021-11-30 2023-05-02 华中农业大学 一株巴士链球菌及其在生物合成儿茶素衍生物中的应用
TW202332763A (zh) * 2021-12-01 2023-08-16 美商聯邦生物公司 微生物菌群
WO2023100989A1 (ja) * 2021-12-02 2023-06-08 国立大学法人東北大学 下痢治療剤および牛の下痢治療方法
CN115197865B (zh) * 2022-02-10 2023-10-03 江南大学 一株可促进生长与生殖发育的富锌长双歧杆菌

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3628161B1 (en) * 2012-11-23 2023-04-05 Seres Therapeutics, Inc. Synergistic bacterial compositions and methods of production and use thereof
GB201621123D0 (en) * 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN111212655A (zh) * 2017-08-14 2020-05-29 赛里斯治疗公司 用于治疗胆汁淤积性疾病的组合物和方法

Also Published As

Publication number Publication date
CA3175041A1 (en) 2021-09-16
EP4117694A1 (en) 2023-01-18
US20230125976A1 (en) 2023-04-27
IL296218A (en) 2022-11-01
AU2021234298A1 (en) 2022-09-29
WO2021183701A1 (en) 2021-09-16
KR20220166803A (ko) 2022-12-19
JP2023517235A (ja) 2023-04-24

Similar Documents

Publication Publication Date Title
MX2022011260A (es) Consorcios microbianos para el tratamiento de enfermedad.
MY191407A (en) Certain chemical entities, compositions and methods
UY36894A (es) Composiciones estables de inoculantes y métodos para producirlas
EP2440210A4 (en) METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES
WO2007130655A3 (en) Phage derived antimicrobial activities
WO2016086210A8 (en) Probiotic and prebiotic compositions, and methods of use thereof for treatment and prevention of graft versus host disease
MX2009001188A (es) Compuestos quimicos.
MX2014004644A (es) Macrociclos peptidomimeticos.
GB201020032D0 (en) Composition
MX2009009292A (es) Compuestos activos en ppar.
MX2009009290A (es) Compuestos activos en ppar.
CY1116056T1 (el) Αντιβακτηριακη θεραπεια συνδυασμου για τη θεραπεια gram θετικων βακτηριακων μολυνσεων
WO2011153491A3 (en) Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
GB0812642D0 (en) Compounds
MX2010001692A (es) Ciertas entidades quimicas, composiciones y metodos.
EA200802111A1 (ru) Имплантаты для лечения состояний, ассоциируемых с допамином
WO2019169333A8 (en) Afibrotic compounds, devices, and uses thereof
UA117922C2 (uk) Насичені азотовмісні та n-ациловані гетероцикли, що посилюють дію активного антибіотика проти мікобактерій
MX2022007285A (es) Compuestos, polimeros, dispositivos y usos de los mismos.
WO2011041701A3 (en) Inplantable contrast agents and methods
AU2022357226A1 (en) Lpxc inhibitors and uses thereof
NZ608763A (en) Unicondylar meniscal bearing knee replacement
WO2023102091A3 (en) Microbial consortia
EA201101113A1 (ru) Пестицидные комбинации
WO2007092590A3 (en) Anti-mycobacterial formulation comprising octanesulphonylacetamide (osa), nonanesulphonylacetamide (nsa) and decanesulphonylacetamide (dsa)